title: [Disseminated carcinoma of the prostate: monotherapy or complete androgenic blockade?].
abstract: OBJECTIVE
  To review the different modalities of hormonal therapy in the treatment of prostatic cancer and to analyze the results achieved by monotherapy and total androgen blockade.
  
  
  METHODS
  The results of different studies published in the literature are reviewed, with special reference to the results of the more important randomized studies.
  
  
  CONCLUSIONS
  Hormone suppression achieves a response rate of more than 75% and is therefore a valid alternative in the management of metastatic cancer of the prostate. Monotherapy and total androgen blockade have similar survival rates and disease free intervals. However, the results according to prognostic groups are significantly better for those treated with total androgen blockade and has less severe disease, suggesting early treatment.
authors.affiliation: Servicio de Urología, Hospital Juan Canalejo, La Coruña, España.
authors.forename: M
authors.initials: M
authors.lastname: González Martín
authors.forename: F
authors.initials: F
authors.lastname: Gómez Veiga
authors.forename: L
authors.initials: L
authors.lastname: Alvarez Castelo
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use*; D000728:Androgens / Q000097:blood; D017281:Cost of Illness; D004967:Estrogens / Q000009:adverse effects; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives; D006801:Humans; D008297:Male; D009376:Neoplasms, Hormone-Dependent / Q000097:blood / Q000188:drug therapy* / Q000191:economics; D009919:Orchiectomy; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000191:economics; D011788:Quality of Life
chemical_list: D000726:Androgen Antagonists; D000728:Androgens; D004967:Estrogens; D007987:Gonadotropin-Releasing Hormone
vernacular_title: Carcinoma de próstata diseminado ?monoterapia o bloqueo androgénico completo?